OFFICE-BASED BUPRENORPHINE THERAPY FOR …
Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Pharmacists
Download OFFICE-BASED BUPRENORPHINE THERAPY FOR …
Information
Domain:
Source:
Link to this page:
Related documents
Overview - Qsymia REMS
www.qsymiarems.comOverview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia to ensure the benefits of Qsymia outweigh the increased risk of teratogenicity.
How FDA Approves Drugs and Regulates Their …
fas.orgHow FDA Approves Drugs and Regulates Their Safety and Effectiveness Congressional Research Service 2 enacted,5 increasing safety provisions and requiring that manufacturers show drugs to be effective as well.6 The FFDCA has been amended many times, leading to FDA’s current mission of assuring
IMPORTANT DRUG WARNING - Clozapine REMS
www.clozapinerems.comIMPORTANT DRUG WARNING Regarding Clozapine-Containing Products Indications and Important Selected Safety Information About Clozapine-Containing Products
Clozapine and the Risk of Neutropenia
www.clozapinerems.comClozapine can cause severe neutropenia, which can lead to serious infections and death. Severe neutropenia occurs in a small percentage of patients taking clozapine.
Risk Evaluation and Mitigation Strategies (REMS)
www.pharmacytechtopics.comJan 31, 2014 · PHARMACY TECH TOPICS TM — JANUARY 2012 2 Pharmacy Tech Topics™ January 2012 Faculty Disclosure It is the policy of the Illinois Council of Health-System Pharmacists (ICHP) to insure balance and objectivity in all its